PL2146704T3 - Zastosowanie kompozycji zawierającej formoterol i dipropionian beklometazonu do leczenia zaostrzenia astmy - Google Patents

Zastosowanie kompozycji zawierającej formoterol i dipropionian beklometazonu do leczenia zaostrzenia astmy

Info

Publication number
PL2146704T3
PL2146704T3 PL08748930.8T PL08748930T PL2146704T3 PL 2146704 T3 PL2146704 T3 PL 2146704T3 PL 08748930 T PL08748930 T PL 08748930T PL 2146704 T3 PL2146704 T3 PL 2146704T3
Authority
PL
Poland
Prior art keywords
formoterol
exacerbation
asthma
treatment
composition
Prior art date
Application number
PL08748930.8T
Other languages
English (en)
Inventor
Paolo Chiesi
Ivano Rondelli
Daniela Acerbi
Gianluigi Poli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38458097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2146704(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PL2146704T3 publication Critical patent/PL2146704T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL08748930.8T 2007-04-19 2008-04-16 Zastosowanie kompozycji zawierającej formoterol i dipropionian beklometazonu do leczenia zaostrzenia astmy PL2146704T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07007930A EP1982709A1 (en) 2007-04-19 2007-04-19 Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma

Publications (1)

Publication Number Publication Date
PL2146704T3 true PL2146704T3 (pl) 2016-09-30

Family

ID=38458097

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16152451T PL3034073T3 (pl) 2007-04-19 2008-04-16 Zastosowanie kompozycji zawierającej formoterol i dipropionian beklometazonu do zapobiegania i/lub leczenia zaostrzenia astmy
PL08748930.8T PL2146704T3 (pl) 2007-04-19 2008-04-16 Zastosowanie kompozycji zawierającej formoterol i dipropionian beklometazonu do leczenia zaostrzenia astmy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16152451T PL3034073T3 (pl) 2007-04-19 2008-04-16 Zastosowanie kompozycji zawierającej formoterol i dipropionian beklometazonu do zapobiegania i/lub leczenia zaostrzenia astmy

Country Status (29)

Country Link
US (1) US20080261932A1 (pl)
EP (3) EP1982709A1 (pl)
JP (2) JP5492072B2 (pl)
KR (3) KR20100014408A (pl)
CN (1) CN101657191B (pl)
AU (1) AU2008241045C1 (pl)
BR (1) BRPI0809800A2 (pl)
CA (1) CA2684539A1 (pl)
CO (1) CO6220945A2 (pl)
CY (1) CY1117568T1 (pl)
DK (1) DK2146704T3 (pl)
EA (1) EA018589B1 (pl)
ES (2) ES2568497T3 (pl)
GE (1) GEP20145999B (pl)
HR (1) HRP20160588T1 (pl)
HU (1) HUE029263T2 (pl)
IL (1) IL201632A (pl)
MA (1) MA31315B1 (pl)
ME (1) ME00945B (pl)
MX (1) MX2009010851A (pl)
MY (1) MY169579A (pl)
NZ (1) NZ580526A (pl)
PL (2) PL3034073T3 (pl)
RS (1) RS54874B1 (pl)
SI (1) SI2146704T1 (pl)
TN (1) TN2009000390A1 (pl)
TR (1) TR201909857T4 (pl)
UA (1) UA100237C2 (pl)
WO (1) WO2008128685A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1982709A1 (en) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
RS53514B1 (sr) * 2009-10-02 2015-02-27 Chiesi Farmaceutici S.P.A. Farmaceutske aerosolne formulacije od formoterola i beklometazon dipropionata
CN102247597B (zh) * 2010-05-19 2015-01-07 天津金耀集团有限公司 一种糖皮质激素与支气管扩张剂的吸入剂
MX368199B (es) * 2012-01-25 2019-09-24 Chiesi Farm Spa Formulación en polvo seco que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación.
US11052202B2 (en) * 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
AU2017328908B2 (en) * 2016-09-19 2020-04-02 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
CN107233311B (zh) * 2017-06-27 2020-12-04 长风药业股份有限公司 一种以阿福特罗和格隆溴铵为活性成分的雾化剂及其制备方法
AU2019282562A1 (en) * 2018-06-04 2021-01-21 Lupin Inc. Stable pharmaceutical compositions for pressurized metered dose inhalers
EP4611733A1 (en) * 2022-11-03 2025-09-10 Dana-Farber Cancer Institute, Inc. Methods of treating anemia using formoterol or a pharmaceutically acceptable salt thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
SG48301A1 (en) 1991-12-18 1998-04-17 Astra Ab New combination
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
JP5392880B2 (ja) 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
FI20002177A0 (fi) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
IL163843A0 (en) 2002-03-01 2005-12-18 Chiesi Farma Spa Formoterol superfine formulation
EP1982709A1 (en) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma

Also Published As

Publication number Publication date
ES2740103T3 (es) 2020-02-05
MX2009010851A (es) 2009-11-05
KR20150082699A (ko) 2015-07-15
BRPI0809800A2 (pt) 2014-10-07
HUE029263T2 (en) 2017-02-28
PL3034073T3 (pl) 2019-11-29
CN101657191B (zh) 2014-06-11
AU2008241045C1 (en) 2023-06-15
IL201632A (en) 2016-09-29
HRP20160588T1 (hr) 2016-07-01
MY169579A (en) 2019-04-22
WO2008128685A1 (en) 2008-10-30
KR20150038618A (ko) 2015-04-08
EP3034073B1 (en) 2019-06-12
DK2146704T3 (en) 2016-05-23
CO6220945A2 (es) 2010-11-19
US20080261932A1 (en) 2008-10-23
NZ580526A (en) 2012-07-27
RS54874B1 (sr) 2016-10-31
SI2146704T1 (sl) 2016-05-31
KR101668203B1 (ko) 2016-10-20
AU2008241045A1 (en) 2008-10-30
EP2146704B1 (en) 2016-03-23
EP1982709A1 (en) 2008-10-22
TR201909857T4 (tr) 2019-07-22
CA2684539A1 (en) 2008-10-30
GEP20145999B (en) 2014-01-10
CY1117568T1 (el) 2017-04-26
HK1137357A1 (en) 2010-07-30
JP2010524873A (ja) 2010-07-22
IL201632A0 (en) 2010-05-31
EA200901201A1 (ru) 2010-04-30
EA018589B1 (ru) 2013-09-30
CN101657191A (zh) 2010-02-24
UA100237C2 (uk) 2012-12-10
MA31315B1 (fr) 2010-04-01
ME00945B (me) 2012-06-20
TN2009000390A1 (en) 2010-12-31
EP3034073A1 (en) 2016-06-22
ES2568497T3 (es) 2016-04-29
JP5492072B2 (ja) 2014-05-14
AU2008241045B2 (en) 2013-06-20
EP2146704A1 (en) 2010-01-27
JP2014005312A (ja) 2014-01-16
KR101621676B1 (ko) 2016-05-16
KR20100014408A (ko) 2010-02-10

Similar Documents

Publication Publication Date Title
SI2146704T1 (sl) Uporaba sestavka, ki obsega formoterol in beklometazon dipropionat, za zdravljenje poslabšanja stanja astme
PL1919450T3 (pl) Kompozycja liposomowa zawierająca lek przeciwhistaminowy i kortykosteroid oraz jej zastosowanie do wytwarzania leku do leczenia nieżytu nosa i chorób spokrewnionych
AP2490A (en) Therapeutic compositions and the use thereof
IL222542A (en) Use of a compound to prepare a drug to inhibit and diagnose proteinuria in the lung
IL202744A0 (en) Therapeutic compositions and the use thereof
IL221573A (en) Imidazoquinolines and their use in the preparation of drugs for the treatment of proliferative and inflammatory and obstructive pulmonary diseases
EP2007385A4 (en) CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
GB0721739D0 (en) medicinal inhalation devices and components thereof
EP2029013A4 (en) NANOELECTRONIC BREAST ANALYZER AND ASTHMA MONITORING SYSTEM
IL213959A0 (en) Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma
AP2657A (en) Anti-inflammatory compositions comprising tetracyclines and use thereof in therapy
IL190522A (en) A medicinal product containing hydrocarbon testosterone gel and use of testosterone to make the preparation
PL2121025T3 (pl) Sposoby i kompozycje dla dostarczania czynnika terapeutycznego
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
IL200764A0 (en) Composition comprising epha3 antibodies and use thereof for the treatment of solid tumors
IL194185A0 (en) Formuations of low dose diclofenac and beta-cyclodextrin
EP2205301A4 (en) MEDICAL INHALATION DEVICES AND COMPONENTS THEREOF
IL193369A0 (en) A nebulizer formulation and kit containing formoterol and budesonide
EP2056857A4 (en) PHARMACEUTICAL COMPOSITIONS WITH CCL2 AND THEIR USE IN THE TREATMENT OF INFLAMMATION
EP2004216A4 (en) AGENT FOR THE TREATMENT OF HORMONO-DEPENDENT DISORDERS AND USES THEREOF
ZA201005282B (en) Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
PT2482799E (pt) Formulações farmacêuticas de aerossol de formoterol e de dipropionato de beclometasona
TWI370735B (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
EP1982724A4 (en) THERAPEUTIC AGENT FOR THE TREATMENT OF METABOLIC SYNDROME AND FOODS CONTAINING THE SAME
GB0607402D0 (en) Therapeutic composition and use